METAPS-INC.
Metaps Inc. (HQ: Tokyo, CEO: Katsuaki Sato, hereafter “Metaps”) developer of the Android app monetization platform, ‘metaps’ has announced the commencement of a new service called ‘metaps Exchanger’ for Android apps, that allows the mutual exchange of user traffic between participant apps on the network, and performance optimization of their app icons.
Mutual Exchange of Traffic
Android Apps that are integrated with metaps Exchanger can show full screen ads at any point inside their app. Based on the number of times the developer shows the ads, they will proportionally receive the right for their own icon to be displayed in other metaps Exchanger integrated apps. Therefore, just by showing the metaps Exchanger ads in their own app, developers are given the chance to acquire users at no cost - A great prospect for developers who do not have the budget to launch large scale acquisition campaigns. Furthermore, only 2 lines of code are required to be added, and can take just 5 minutes for the most basic integration.
Optimization of Icon Performance
By registering multiple versions of their icon, the developer can perform A/B tests to determine which design delivers the most impact to users on the network, based on each icon’s click through rate (CTR) and conversion rate (CVR). Reports of the test results can be viewed at any time.
Since the changes to layout in the latest Google Play Store site renewal, a higher emphasis has been put on the creative design of the app icon and the impression it creates. Therefore, by optimizing the effectiveness of the icon, higher conversions can be expected from Google Play Store or any other Android app market place.
Monetize While Acquiring Users
Once an advertised app is downloaded, the ad revenue is paid to the developer displaying the ad. Unlike conventional banner ads, the Exchanger full-screen ad can be shown as an interstitial at any point inside the app. Additionally, since the ads are displayed full-screen, there is no visual impact on the UI design, and higher conversion rates can be expected.
Users tend not to click on conventional banner ads, and any impressions were generally wasted when click through was not achieved. However, by tying up the number of impressions, whether users click through or not, with the number of times the developer’s own icons can be displayed inside other apps on the Exchanger network, each impression is never a wasted potential, allowing for more opportunity to acquire users as well as monetization.
A Global Exchange Network
As long as the developer’s app is available on Google Play, it is possible to tap into metaps Exchanger’s global network. By exchanging traffic with other apps around the world, it is possible to increase user acquisitions in a self-propagating manner.
metaps Exchanger Product Page URL:
http://exchanger.metaps.com/
About Metaps
Metaps is an Android monetization platform that supports developers by providing them with the necessary tools to attract customers, engage users, and monetize traffic.
Home Page: http://www.metaps.com/
Facebook:
http://www.facebook.com/metaps
SlideShare:
http://www.slideshare.net/metaps
- Metaps Inc. (Tokyo HQ)
6-29-8 Shinjuku, Shinjuku-ku, Tokyo, Japan
- Metaps Pte. Ltd.
100 Cecil Street, The Globe No. 05-01, Singapore
- Metaps International
645 Harrison Street No. 200, San Francisco, CA,
USA
- Metaps Hong Kong
Suite 1008 Prosperity Millennia Plaza, 663
King's Road, Quarry Bay, Hong Kong
- Metaps Korea
No. 303, 3F Sun Bldg, 677-12, Yeoksam-dong, Gangnam-gu,
Seoul, Korea
Contact:
Metaps Inc.
Hiroaki Kato, +81-3-5366-3790
info@metaps.com
Fax:
+81-3-5366-3791
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum